Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390617 | 0.85 | HTR2A (0.42) | HTR2AHTR2CHTR2BDPP4 | |
| SCHEMBL13455119 | 0.82 | NPY5R (0.41) | NPY5RLCKJAK3BTKPDE7A | |
| SCHEMBL17001889 | 0.81 | CHRM2 (0.41) | HTR2AHTR2CHTR2BNPY5RPDE7A | |
| SCHEMBL23714592 | 0.78 | MAPK1 (0.43) | NPY5RLCKJAK3BTKPDE7A | |
| SCHEMBL24845143 | 0.77 | DRD2 (0.32) | NPY5RLCKJAK3 | |
| SCHEMBL15448411 | 0.75 | NPY5R (0.38) | NPY5RPDE7A | |
| SCHEMBL23138574 | 0.74 | DPP4 (0.33) | DPP4 | |
| SCHEMBL21222493 | 0.74 | MAPK1 (0.39) | NPY5RLCKJAK3BTKPDE7A | |
| SCHEMBL10801442 | 0.74 | MAPK1 (0.39) | NPY5RLCKJAK3BTKPDE7A | |
| SCHEMBL23138568 | 0.74 | DPP4 (0.33) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022150707-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, Inc. (US) | 2022-07-14 | — | — | WO | disclosed |